FDG-PET/CT-based restaging may alter initial management decisions and clinical outcomes in patients with locally advanced pancreatic carcinoma planned to undergo chemoradiotherapy

Cancer Imaging

Volumn 13, Issue 3, 2013, Pages 423-428

  Topkan, Erkan ^a   Parlak, Cem ^a   Yapar, Ali Fuat ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Chemoradiotherapy; Locally advanced pancreatic carcinoma; Management decision change; Restaging PET CT; Survival outcome

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIARRHEA; DISEASE SEVERITY; DISTANT METASTASIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LOCALLY ADVANCED PANCREATIC CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CARCINOMA; PANCREAS RESECTION; PATIENT SELECTION; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; SENSITIVITY AND SPECIFICITY; STOMACH OBSTRUCTION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; CHEMORADIOTHERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84885574737     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2013.0035     Document Type: Article

References (20)

1. Russo S, Butler J, Ove R, Blackstock AW. Locally advanced pancreatic cancer: a review. Semin Oncol 2007; 34: 327-334 PMid:17674961. (Pubitemid 47176622)
2. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group. Cancer 1985; 56: 2563-2568 PMid:2864997.
3. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 1985; 3: 373-378 PMid:3973648. (Pubitemid 15132005)
4. Kinney T. Evidence-based imaging of pancreatic malignancies. Surg Clin North Am 2010; 90: 235-249 PMid:20362784.
5. Rose DM, Delbeke D, Beauchamp RD, et al. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999; 229: 729-737 PMid:10235532.
6. Casneuf V, Delrue L, Kelles A, et al. Is combined 18F-fluorodeoxyglucose- positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg 2007; 70: 331-338 PMid:18330088. (Pubitemid 351251957)
7. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 1S-93S. PMid:11483694. (Pubitemid 32423895)
8. Nguyen VX, Nguyen CC, Nguyen BD. 18F-FDG PET/CT imaging of the pancreas: spectrum of diseases. JOP 2011; 12: 557-566 PMid:22072244.
9. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 2009; 71: 164-174
10. Parsons CM, Sutcliffe JL, Bold RJ. Preoperative evaluation of pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 2008; 15: 429-435 PMid:18670846.
11. Heinrich S, Goerres GW, Schäfer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005; 242: 235-243 PMid:16041214. (Pubitemid 41033440)
12. Delbeke D, Martin WH. PET and PET/CT for pancreatic malignancies. Surg Oncol Clin North Am 2010; 19: 235-254
13. Topkan E, Yavuz AA, Aydin M, Onal C, Yapar F, Yavuz MN. Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinoma. J Exp Clin Cancer Res 2008; 27: 41. PMid:18808725.
14. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782 PMid:10673991. (Pubitemid 29512308)
15. Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009; 27: 2269-2277 PMid:19307501.
16. Delbeke D, Rose DM, Chapman WC, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999; 40: 1784-1791 PMid:10565771. (Pubitemid 29523570)
17. Mertz HR, Sechopoulos P, Delbeke D, Leach SD. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 2000; 52: 367-371 PMid:10968852.
18. Delbeke D, Martin WH. Update of PET and PET/CT for hepatobiliary and pancreatic malignancies. HPB (Oxford) 2005; 7: 166-179 (Pubitemid 41535846)
19. Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 2006; 40: 923-929 PMid:17063113. (Pubitemid 44690768)
20. Wakabayashi H, Nishiyama Y, Otani T, et al. Role of 18F- fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 2008; 14: 64-69 PMid:18176963. (Pubitemid 351314328)